Brigatinib

Brigatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the bodys.

How Brigatinib works?
Brigatinib is an anticancer drug that is used to treat non-small cell lung cancer (NSCLC) that has progressed to other regions of the body. Brigatinib belongs to the kinase inhibitor class of drugs. It works by preventing cancer cells from multiplying by stopping the action of an aberrant protein. This slows or stops cancer cells from spreading.
Common side effects of Brigatinib
nausea, diarrhea, vomiting, constipation, tiredness, rash, headache, numbness, pain, tingling, or burning feeling in the feet or hands back or joint pain, loss of appetite, difficulty falling asleep or staying asleep
How should I take Brigatinib ?
You should take Brigatinib exactly as directed by your doctor. It should be started by doctors who have experience in administering cancer medicines. Take it once a day with or without food. Do not drink grapefruit juice or eat grapefruit during your treatment with Brigatinib, as the chances of side effects may be more.
What should I do if I forget a dose?
If you miss a dose of Brigatinib by less than 12 hours, take the missed dose as soon as you remember it and then take the next dose at the scheduled time. However, if you miss a dose by more than 12 hours, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
In case of emergency/overdose
In case of overdose, call the poison control helpline. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call a doctor.

Contact Us







    Brigatinib is an orally accessible receptor tyrosine kinase inhibitor with potential antineoplastic action for the anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR). Brigatinib binds to ALK kinase and ALK fusion proteins, as well as EGFR and mutant versions, and inhibits them. This inhibits ALK kinase and EGFR kinase, impairs their signalling pathways, and ultimately stops tumour cells from growing in vulnerable tumour cells. Furthermore, AP26113 appears to be resistant to mutations. ALK is a member of the insulin receptor superfamily and is involved in nervous system development. ALK gene rearrangements and dysregulation have been linked to a variety of cancers. In a variety of cancer cell types, EGFR is overexpressed.

    PLEASE NOTE:

    The above information is an educational aid only. It is not intended as medical advice for individual conditions or treatments. Talk to your doctor, nurse or pharmacist before following any medical regimen to see if it is safe and effective for you.

    Enquiry Now
    Translate »

    Want Information?